Availability of genome-matched therapy based on clinical practice

Area of Science:

• Oncology
• Genomics
• Precision Medicine

Background:

• Comprehensive genomic profiling (CGP) offers potential for genome-matched therapies in advanced cancer.
• Current availability rates for these targeted therapies remain low.
• This study examines CGP utility and access barriers from a clinical viewpoint.

Purpose of the Study:

• To assess the utility of CGP in identifying druggable genomic alterations across various cancer types.
• To investigate barriers hindering patient access to genome-matched therapies.
• To propose strategies for improving therapy availability.

Main Methods:

• Retrospective analysis of 653 patients with 30 cancer types who underwent CGP.
• Identification of druggable genomic alterations and assessment of genome-matched therapy availability.
• Evaluation of barriers to accessing targeted therapies, including performance status.

Main Results:

• Overall genome-matched therapy availability was 9.5%.
• High rates of druggable alterations were found in thyroid (100%) and lung (76%) cancers; sarcoma had 15.2%.
• Therapy availability was highest for sarcoma (60%) and head and neck cancer (HNC) (40%).
• Multiple barriers affected 63.5% of patients; 11.8% were excluded due to poor performance status.

Conclusions:

• CGP is clinically useful for sarcoma and HNC, in addition to lung cancer.
• Front-line CGP has the potential to enhance genome-matched therapy accessibility.
• Addressing barriers is crucial for realizing the full benefit of precision oncology.